Literature DB >> 1677582

The effects of cholinergic drugs and cholinergic-rich foetal neural transplants on alcohol-induced deficits in radial maze performance in rats.

H Hodges1, Y Allen, J Sinden, S N Mitchell, T Arendt, P L Lantos, J A Gray.   

Abstract

Chronic alcohol (20% v/v in drinking water for 28 weeks) impaired acquisition of radial maze spatial and associative tasks by increasing both within-trial working and long-term reference memory errors; animals with high (above the median of 100 mg/100 ml) blood alcohol concentrations (BACs) during treatment were significantly more impaired than those with BACs below the median. Alcohol-treated rats showed improvements in radial maze performance after treatment with cholinergic agonists (arecoline and nicotine) and disruption with antagonists (scopolamine and mecamylamine) at low doses which did not affect controls. These effects were more pronounced for working than reference memory, and not manifest with the peripherally acting antagonists hexamethonium and N-methylscopolamine. Transplants into cortex and hippocampus of cholinergic-rich basal forebrain (BF) and ventral mesencephalon (VM) foetal neural tissue improved radial maze performance of alcohol-treated rats to control level over a period of 9-12 weeks after grafting. Cholinergic-poor foetal hippocampal (HC) grafts were without effect. BF and VM, but not HC, grafts showed dense acetylcholinesterase (AChE) staining, tyrosine-hydroxylase staining was most pronounced in VM sections and dopamine-beta-hydroxylase staining was minimal in all grafts. Choline acetyltransferase (ChAT) activity was significantly reduced in cortex and hippocampus of alcohol-treated rats, except those given cholinergic-rich transplants. Alcohol treatment also significantly reduced AChE-positive cell counts in the nucleus basalis, medial septal and diagonal band brain areas, at the sources of the forebrain cholinergic projection system (FCPS). Cortical levels of noradrenaline were significantly reduced in all alcohol-treated rats, regardless of transplant, whereas cortical dopamine content was significantly elevated in all rats receiving transplants, regardless of behavioural effect, but not in alcohol-treated controls. Forebrain serotonin levels were not significantly altered by grafting or alcohol treatment. These results suggest that damage to the FCPS, as shown by reduced ChAT activity in target areas, and reduced AChE cell counts in projection areas, played an important part in the radial maze deficits displayed by alcohol-treated rats, since these animals were sensitive to cholinergic drug challenge, and cholinergic-rich transplants from two different sites in foetal brain elevated ChAT activity and restored cognitive function. In contrast alcohol- or graft-induced alterations in other transmitter systems did not correlate with the pattern of behavioural deficit and recovery.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677582     DOI: 10.1016/s0166-4328(05)80048-8

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  17 in total

Review 1.  The current state of S. S. Korsakov's concept of alcoholic polyneuritic psychosis.

Authors:  Yu P Sivolap
Journal:  Neurosci Behav Physiol       Date:  2005-11

Review 2.  Neuropathology of thiamine deficiency: an update on the comparative analysis of human disorders and experimental models.

Authors:  P J Langlais; S X Zhang; L M Savage
Journal:  Metab Brain Dis       Date:  1996-03       Impact factor: 3.584

3.  Impulsive choice and anxiety-like behavior in adult rats exposed to chronic intermittent ethanol during adolescence and adulthood.

Authors:  Jana Mejia-Toiber; Nathalie Boutros; Athina Markou; Svetlana Semenova
Journal:  Behav Brain Res       Date:  2014-02-22       Impact factor: 3.332

4.  Periadolescent ethanol exposure reduces adult forebrain ChAT+IR neurons: correlation with behavioral pathology.

Authors:  C L Ehlers; J R Criado; D N Wills; W Liu; F T Crews
Journal:  Neuroscience       Date:  2011-10-18       Impact factor: 3.590

5.  Preliminary findings on the interactive effects of IV ethanol and IV nicotine on human behavior and cognition: a laboratory study.

Authors:  Elizabeth Ralevski; Edward B Perry; D Cyril D'Souza; Vanessa Bufis; Jacqueline Elander; Diana Limoncelli; Michael Vendetti; Erica Dean; Thomas B Cooper; Sherry McKee; Ismene Petrakis
Journal:  Nicotine Tob Res       Date:  2011-12-16       Impact factor: 4.244

6.  The selective 5-HT3 receptor antagonist, WAY100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system.

Authors:  H Hodges; P Sowinski; J D Sinden; C A Netto; A Fletcher
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

Review 7.  Alcohol-related amnesia and dementia: animal models have revealed the contributions of different etiological factors on neuropathology, neurochemical dysfunction and cognitive impairment.

Authors:  Ryan P Vetreno; Joseph M Hall; Lisa M Savage
Journal:  Neurobiol Learn Mem       Date:  2011-01-21       Impact factor: 2.877

8.  Cholinergic dysfunction and amnesia in patients with Wernicke-Korsakoff syndrome: a transcranial magnetic stimulation study.

Authors:  Raffaele Nardone; Jürgen Bergmann; Pierpaolo De Blasi; Martin Kronbichler; Jörg Kraus; Francesca Caleri; Frediano Tezzon; Gunther Ladurner; Stefan Golaszewski
Journal:  J Neural Transm (Vienna)       Date:  2009-12-04       Impact factor: 3.575

9.  Interactions between chronic ethanol consumption and thiamine deficiency on neural plasticity, spatial memory, and cognitive flexibility.

Authors:  Lindsey C Vedder; Joseph M Hall; Kimberly R Jabrouin; Lisa M Savage
Journal:  Alcohol Clin Exp Res       Date:  2015-09-30       Impact factor: 3.455

10.  Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease.

Authors:  G M Jones; B J Sahakian; R Levy; D M Warburton; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.